The graph in Figure S9c shows the comparison of NK-mediated cytotoxicity levels between PBMC from CLL treated with IL15 or scFvB1IL15 and non-treated PBMCs from HDs, taking into account the percentages of NK cells in each sample (respectively, 426 ± 99.9 LU30/107 effector cells for PBMCs from CLL patients treated with IL15 and 2026.72 ± 414.92 LU30/107 effector cells for PBMCs from CLL patients treated with scFvB1IL15 versus 218.44 ± 77.06 LU30/107 effector cells for non-treated PBMCs from HDs). This evidence concerns the gene IL15 and B-cell chronic lymphocytic leukemia.